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Introduction 
 
Today chronic liver disease is developing and liver 
cirrhosis mortality is increasing. Cirrhosis is a 
chronic liver damage. In this disease, normal liver 
tissue and its normal function are impaired. As the 
disease progresses the symptoms of decreased 
mental and physical function and biochemical fail-
ures appear. The result of this process leads to 
complete liver failure and death (1).  
Etiology of cirrhosis is different in variety parts of 
the world such as America and countries with 
high alcohol consuming, the most common cause 
of cirrhosis is associated with alcohol-related cir-
rhosis, and other main causes of the disease are 
hepatitis B and C (2). Cirrhosis is most common 
in men ages 20 to 59 year, at the age of productiv-
ity (2, 3). 
Liver cirrhosis leads to 800,000 yearly deaths, 
1.3% of total deaths, in the world. According to 
WHO classification is one of the eighteen signifi-
cant causes of death. The five year survival of pa-
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tients with alcoholic cirrhosis and nonalcoholic 
cirrhosis are 36% and 14%, respectively (4). 
In recent years the use of health care services in 
the patients has been increased, for example, in 
Britain between 1989 and 2002, the hospital re-
ception and the mortality of chronic liver disease, 
such as cirrhosis, have been increased. Moreover, 
cirrhosis in Europe led to the loss of 3.1 million 
Disability Adjusted Life Years (DALYs) (2% of 
total DALYs) which is the ninth cause of disease 
burden. The years lost due to disability (YLD) as-
sociated with cirrhosis have been estimated more 
than 3.79 million in 2000 (4). 
In the recent years, many studies have been per-
formed to estimate the economic burden of hepa-
titis and cirrhosis of the liver, because cirrhosis is 
one of the most important health problems and 
has a significant rate of mortality, morbidity, social 
psychological and economic burden (5-8). For 
example a study analyzed the scale and trends of 
the social and economic costs of liver disease in 
Korea for 5 years, and social and economic costs 
of illness were predicted 5858 KRW billion in 
2004, the cost of production lost in premature 
deaths caused by liver cirrhosis was estimated 
5572 KRW billion in 2005, 8104 KRW billion in 
2006, 6095 KRW billion in 2007, and 5689 KRW 
billion in 2008 (9). In South Korea total resulting 
costs (direct plus indirect) from HBV related dis-
ease was 936.1 KRW billion (833.1 million USD) 
which 45.3% of that was attributable to cirrhosis 
(10). Besides, a study in China examined the total 
annual cost per patient for CHB, compensated 
cirrhosis, decompensated cirrhosis, and liver carci-
nomas (7). Liver cirrhosis has imposed enormous 
direct and indirect costs on society in Germany 
and Mexico, as well (11, 12). The study performed 
in Mexico to estimate the annual cost of treating 
patients with cirrhosis at the Mexican Institute of 
Social Security. They determine the cost of cirrho-
sis according the three stages of disease (Child-
Pugh A, Child-Pugh B and Child-Pugh C) using 
micro-costing techniques and medical experts. 
The annual cost of treatment, in USA dollars, by 
Child-Pugh stage was: a) micro-costing results: 
$1110.17 stage A, $549.55 stage B and $348.16 
stage C; b) opinion of medical experts: $1 633.64, 
$6564.04 and $19660.35, respectively; and c) IMSS 
costs: $4269.00, $16949.63 and $30249.25, respec-
tively (13). 
According to increasing the prevalence of liver 
cirrhosis and its heavy costs that have been im-
posed to the human societies and according to 
lack of information about the costs of the disease 
in Iran, this study has been performed. It is nota-
ble that there is no comprehensive study about 
economic aspects of liver cirrhosis in Iran so far. 
Also, having the correct information about the 
cost of diseases, it could be useful in making ap-
propriate decisions about prevention and treat-
ment of diseases. The aim of this study was to es-
timate the direct and indirect costs of liver cirrho-
sis and out of pocket payment as well. 
 
Materials and Methods 
 
Cost analysis 
This is a descriptive and a retrospective study per-
formed by cost-of-illness method based on the 
human capital approach. In this method, three 
domains should be determined, first the approach 
is incidence-based or prevalence-based, second 
the approach is bottom-up or top-down, and third 
how the direct and indirect costs will be deter-
mined (12). In the current study, prevalence-based 
and bottom-up approaches have been used and 
the method used to determine the cost shall come 
following. Outcome measures of the study were 
direct cost, indirect cost, out of pocket payments 
and total cost of the disease. Costs were consisting 
of expenditures, which happened during March 
2011to February 2012, and the perspective of the 
study was Iranian society. 
 
Types of costs 
The total economic burden of disease consists of 
two parts, first the direct cost, which consists of 
direct non-medical costs and direct medical costs, 
second indirect costs (7). In our study, all costs 
have been considered:  
a) Direct costs: it contains medical and nonmedi-
cal direct costs that they describe following: 
1. Direct medical costs: These costs measure the used 
economic resources for medical care and involve 
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the outpatient costs, inpatient costs, and costs of 
medications (12). Inpatient and outpatient costs or 
annual costs per patient have been calculated ac-
cording to the average number of annual visits, 
diagnostic tests and medications and their price 
and these items were determined from patient’s 
medical records in Shariyati hospital and outpa-
tient centers in Tehran for outpatient and inpa-
tient care, respectively.  
In order to calculate these costs inpatient and 
outpatient patients' medical records were investi-
gated. Diagnosis tests, medication and visit fees 
were retrieved from the Ministry of Health tariff 
in 2011(14). The formulas that have been used 
here are: 
 
 
 
2. Direct nonmedical costs: These costs include trans-
portation costs, for patients and their families, the 
cost of purchasing additional health products due 
to the disease, costs of stay, and cost of home care. 
These were obtained from a questionnaire which 
designed according to the objectives of the study. 
The characteristics of the questionnaire shall come 
in the data source in fallow. 
b) Indirect Costs: Indirect costs are divided into 
two major parts, indirect costs due to disability 
and indirect costs due to death. Indirect costs due 
to disability depend on the number of absent days 
from work, income and average revenue for care-
giver (12). The daily wage was retrieved from Min-
istry of Labor and Social Affair (15) and used to 
calculate income loss for household women and 
anyone who does not have defined income. To 
calculate potential productivity lost due to prem-
ature death, Gross Domestic Product approach 
has been used. The per capita GDP was obtained 
from World Bank data (16). 
We divided disability in two parts, disability 
caused by hospitalization and ambulatory care. 
There are three kinds of potential production lost 
for liver cirrhosis in this study: 
1. Potential production lost by death 
 According to available data and related studies 
(17, 18) the Years of Life Lost due to Fatality 
(YLLF) associated with liver cirrhosis in 2011, and 
the prevalence of disease and probability of annu-
al death in patients (0.0053) were obtained. The 
amount of production lost for one death has been 
calculated by the following formula (19): 
Production lost for premature death for one 
death ∑
       
      
 
                                          
Where here: W = GDP per capita G = economic 
growth rate I = average years lost due to prema-
ture death 
According to World Bank Report (20) GDP Per 
capita in the year 2011, was USD 4,526, which 
was considered. 0.05 and 0.03 use for discounting 
the cost. For developing countries 0.05 usually use 
because the future costs have a little value in now. 
Then we used 0.05 for discounting the costs and 
for GDP growth, according to its average in 30 
past years, 3.7%was considered (16). Then the to-
tal cost of productivity lost caused by death ob-
tained with multiply this by the number of deaths.  
Iran J Public Health, Vol. 44, No.4, Apr 2015, pp. 512-521 
Available at:  http://ijph.tums.ac.ir   515 
The number of deaths and average years lost due 
to premature death was obtained from related 
studies (18, 21). 
 
2. Production lost cause by inpatient care 
The mean of bed-days has been obtained by stud-
ying hospital records and this amount, multiply by 
inpatient cases and daily average wage in Iran 
2011.  
Finally, potential production lost was calculated by 
following formula: production lost in inpatient 
care in 2011 = S × J × Wr (PL inP)            [6]  
where Here: S = the average days of inpatient care 
for cirrhotic patients in 2011 J = The total num-
ber of patients admitted in 2011, Wr = the aver-
age daily wage in 2011.  
 
3. Production lost due to outpatient care 
For calculating the potential production lost from 
outpatient care, the average of visits for each patient 
has been gained by outpatient records. The days 
with a disability because of the disease, and the days 
those losses for patient partners and caregivers have 
been obtained from the questionnaire. This amount 
multiplied by the average daily wage and total outpa-
tients cases as following formula: 
Potential production lost due to outpatient care = 
(U × F × Wr) PL outP                                   [7]  
Where here: U =the average days of outpatient 
care for cirrhotic patients in 2011 F = total num-
ber of cirrhotic patients in 2011 Wr ₌ daily wage in 
2011. 
Finally the total production lost was obtained by 
following formulas:  
Total production lost = (PL f) + (PL inP) + (PL 
outP)                                                                   [8]  
Where here: PL f = production lost due to prema-
ture deaths in 2011, PL inP = production lost for 
inpatient care in 2011, PL outP = production lost 
due to outpatient care in 2011.   Finally the total cost 
has obtained by the sum of the direct and indirect 
costs. 
 
Data Source 
For obtaining required data to calculate the costs, 
all inpatient records in Shariati Hospital of Tehran 
University of Medical Sciences (N=103) and 58 
outpatient records in Tehran Hepatitis Center - 
Baghiatallah Research Center of Gastroenterology 
and Liver disease (THC-BRCGL), and Shariati Gas-
troenterology Research Center of Tehran University 
of Medical Sciences, were selected randomly and 
continuously. It is notable that we need to have an 
average of inpatient care and with use of this records 
obtained it. Also, 50 ambulatory patients have been 
participated in the Tehran Hepatitis Center - Baghi-
atallah Research Center of Gastroenterology and 
Liver disease (THC-BRCGL) and the Shariati Gas-
troenterology Research Center, randomly and con-
tinuously. The criteria for including the patient were: 
1) patients with definitive diagnosis of liver cirrhosis, 
2) patients who pass at least one year with the dis-
ease. They were interviewed via the questionnaire 
which developed based on the National Health Ac-
counts Questionnaire and the objectives of the study. 
This questionnaire has been approved by expert 
opinion. It has two parts, the first part comprises 
demographic information (age, sex, marital status, 
education status, job, number of family members, 
etc.), income, length of illness, and insurance infor-
mation and the second one contains information 
about indirect costs (absenteeism, sick leave, disabil-
ity, etc.) and out of pocket payments. The costing 
analysis has been done with Excel 2010 software.  
 
Sensitivity analysis 
  
Considering that some of the used variables for 
estimating the burden of the disease were uncer-
tain and to evaluate the impact of changes in these 
variables sensitivity analysis was performed. For 
sensitivity analysis the uncertain variables were 
determined, and then the different possible values 
of them used for calculating the costs. The uncer-
tain variable including were the disease prevalence, 
the annual risk of death and life expectancy lost 
due to a premature death. For estimation the total 
cost of the disease 0.0013, 0.0053 and 18 were 
considered for the uncertain variables, respectively. 
 
Results  
 
Table 1 shows the data, their values and the data 
sources that have been used to estimate the eco-
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nomic burden of the disease in Iran. According to 
data in Table 1 and cost of illness method we esti-
mated the total cost and other cost related to the 
liver cirrhosis. Table 2 shows the total cost and 
other sub-costs in US dollar that in here each dol-
lar equals 12260 Iranian Rials, total cost was 
USD164.32 million, direct and indirect costs were 
USD 112.9 million and USD 51.42 million, re-
spectively. The result for the subgroup of costs 
comes following. 
 
Table 1: The used items for estimation of the economic burden of disease (monetary items are in Iran Rials) 
 
Variables  Amount Source  
Population in 2011  75149669 Census of year 2011(26)  
Number of patients with liver cirrhosis  99269 (21)  
Prevalence of the disease  0.0013 (21)  
Probability of hospitalization in a year  0.0571 Medical records and interview  
The average cost of transportation and stay  1419020 Interviews with patient  
The average cost of stay and transportation between cities  1122400 Interviews with patient  
The average cost of transportation within the city  296620 Interviews with patient  
The annual cost of visit in the private sector  780000 Tariff of 2011(14) and interviews  
The average annual cost of visit in public sector   325000 Tariff of 2011(14) and interviews  
The minimum monthly wage  3303000 (15)  
Daily minimum wages  125000 (15)  
Out of pocket payments for medication (for each patient at 
each visit) 
 418000 Interviews with patient  
Out of pocket payments for purchasing the drugs per pa-
tient in 2011 
 2717000 Interviews with patient  
Annual out-of-pocket payments for outpatient care (per patient)  6856583 Interviews with patients, outpatient 
records 
 
Out of pocket payments for the Inpatient care  549600 Interviews with patients, inpatient rec-
ords 
 
The total out of pocket payments in 2011 (per patient)   7406183 Interviews with patients, outpatient 
and inpatient records 
 
 
Table 2: Costs of cirrhosis of the liver disease in Iran, in 2011 (in USD millions) 
 
Direct costs Indirect costs Cost of the 
illness 
Medical non-medical total Production lost due 
to disability 
Production lost due to 
premature death 
total total 
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Total cost 
According to our estimation total cost of cirrhosis 
in Iran in one year is approximately USD164.32 
million (in 2011) which USD 112.9 million is re-
lated to total direct cost (Table2). Also, total indi-
rect cost which the disease imposed to Iranian 
society was USD 51.42 million in 2011. 
 
Direct costs 
Direct costs were the most proportion (68.7%) of 
the total cost of the disease. The most proportion 
of the costs is related to direct medical costs. 62% 
of the total cost is related to medical costs. Direct 
nonmedical costs, the cost of transportation and 
stay, include only 7% of the total cost. Costs due 
to premature mortality were accounted for 23% of 
the total costs. 
The largest portion of the medical costs of the 
disease was related to purchasing outpatient drugs 
(Table 3). Hospitalization costs had a minimum 
portion of the costs. Totally, 97.15% of the direct 
medical costs were related to the outpatient care. 
Besides, the greatest portion of medical cost was 
for outpatient drug (64.12%). 
 
Table 3: Medical costs of liver cirrhosis in 2011 (In USD millions) 
 
Medical costs 
Outpatient costs Inpatient cost Total 
Drug Diagnostic 
costs 
Outpatient visit total Total  
Amount % Amount % Amount % Amount % Amount % Amount % 
65 64.12 27.18 26.8 6.31 6.2 98.5 97.15 2.88 2.84 101.41 100 
 
Out of Pocket Payment (OOP) 
Out of pocket payment is presented in Table 4. 
According to the table total out of pocket was 
USD 55.71 million and 99.59% of out of pocket 
payment was related to outpatient care and 
39.45% of OOP costs were for buying outpatient 
drugs. The lowest portion of out-of-pocket pay-
ment (0.4%) was associated with inpatient care. 
Totally 49.3% of the direct medical costs were 
paid in the form of out of pocket payment. It 
should be noted out-of-pocket payment consists 
of the costs that were paid directly from the pa-
tient (including co-payments, costs of drugs, clini-
cal tests and hospitalization). 
 
Table 4: Out of pocket payments in cirrhosis of the liver in 2011 (in USD million) 
 
 
Indirect costs 
Total production lost due to liver cirrhosis was 
USD 51.42 million in 2011 (Table5). Production 
lost due to disability was USD 12.76 million which 
USD 10.87 million of it is related to production 
lost due to outpatient care for patients and their 
families. The cost of production lost per a death 
has been estimated 72,525 dollars, and total cost 
of production lost due to premature death was 
USD 38.66 million. Also, 75.17% and 14.83% of 
the indirect costs was related to premature deaths 
and disability, respectively. 
 
Out of pocket payments 
For outpatient drugs For outpatient care For inpatient care Total 
percent amount percent amount percent amount percent Amount 
39.45 21.98 99.59 55.48 0.41 0.24 100 55.71 
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Table 5: The cost of production lost according to different prevalence (number of deaths) and in USD millions 
 
Sensitivity analysis 
Considering that the used variables for estimating 
the burden of the disease are uncertain, the sensi-
tivity analysis has been performed. According to 
different values of uncertain variables, related 
costs have been calculated. In Table 6, total cost 
of cirrhotic patients (in USD millions) was ob-
tained by considering the probability of hospitali-
zation equals to 0.0517. The total cost of illness, 
according to prevalence from 0.0011 to 0.0015, 
was 139.41, 151.83, 164.32, 176.74 and USD 
189.23 million, respectively. Total direct cost var-
ied from USD 95.79 million to USD 130.01 mil-
lion and total indirect cost was approximately 
from USD 43.61 million to USD 59.23 million 
according to different prevalence of liver cirrhosis 
in Iran. 
 The cost of production lost due to premature 
death according different number of deaths and 
average life expectancy lost per premature death 
have been shown in Table 5. Minimum and maxi-
mum cost of premature death, for 18 year life ex-
pectancy lost in a death, were USD 32.7 million 
and USD 44.53 million, respectively. In calculating 
total cost, according to the risk of death from cir-
rhosis of the liver (0.0053) and the prevalence of 
the disease (21), we consider 18 and 533, for the 
years of life expectancy lost and the number of 
deaths from diseases, respectively. Therefore, the 
cost of premature death has been estimated USD 
38.66 million. 
 
Table 6: Cost of liver cirrhosis in terms of the likelihood of hospitalization 0.0517 (in USD million) 
 
Prevalence 0.0011 0.0012 0.0013 0.0014 0.0015 
Direct cost for outpatient care  83.6 91.07 98.53 106 113.46 
Cost of outpatient drug 55.18 60.11 65.04 69.96 74.89 
Cost of outpatient diagnostic test  23.06 25.12 27.18 29.24 31.3 
Cost of outpatient visit 5.35 5.83 6.31 6.79 7.27 
Total cost of visit 2.45 2.67 2.89 3.11 3.33 
Production lost due to disability 10.83 11.8 12.76 13.73 14.7 
Production lost due to outpatient care for patients and their family 9.23 10.05 10.87 11.7 12.52 
Production lost due to outpatient care for patients 5.79 6.31 6.83 7.34 7.86 
Production lost due to outpatient care for patients’ family 3.43 3.74 4.05 4.35 4.66 
Production lost due to premature death 32.78 35.68 38.66 41.56 44.53 
Production lost due to inpatient care 1.6 1.75 1.89 2.03 2.18 
The total cost of transportation 9.74 10.61 11.48 12.35 13.22 
 The total cost of transportation between cities and stay 7.71 8.39 9.08 9.77 10.46 
The total cost of transportation within the city 2.04 2.22 2.4 2.58 2.76 
 Out of pocket payments for purchasing drugs  18.65 20.32 21.98 23.65 25.31 
Out of pocket payments for outpatient care 47.07 51.27 55.48 59.68 63.88 
Out of pocket payments for inpatient care 0.2 0.21 0.23 0.25 0.26 
Total out of pocket 47.27 51.49 55.71 59.93 64.15 
Total indirect cost 43.61 47.48 51.42 55.29 59.23 
Total direct cost 95.79 104.35 112.9 121.46 130.01 
Total cost 139.41 151.83 164.32 176.74 189.23 
Production lost according to different prevalence (number of deaths ) Cost per a 
death 
Years of life lost 
0.0015 
(614) 
0.0014 
(573) 
0.0013 
 (533) 
0.0012 
(492) 
0.0011 
(452) 
  
44.53 41.56 38.66 35.68 32.78 0.07 18 
46.72 43.60 40.56 37.44 34.40 0.08 19 
48.89 45.63 42.44 39.18 35.99 0.08 20 
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Discussion 
 
The main objective of this study was the evalua-
tion the economic burden of the liver cirrhosis in 
Iran, 2011. Direct and indirect costs of illness and 
out of pocket payments have been calculated. 
The total cost of illness was 2,014.57 billion Rials 
(USD 164.32 million). The total direct and indirect 
costs were 1384.16 and 630.41 billion Rials (USD 
112.9 million and USD 51.42 million) and direct 
cost is consist of direct medical costs, and direct 
nonmedical costs that were  1243.4 and 140.76 
billion Rials (USD 101.42 million and USD11.48 
million) ,respectively. Indirect costs include the 
productivity lost due to disability (for patient and 
family) and production lost due to premature 
death that was estimated at 156.4 and 473.9 billion 
Rials (12.79 and USD 38.66 millions). 
Also, 68.7% of the total costs were related to di-
rect costs, and indirect costs were 31.3% percent 
of the total cost. In the case of direct costs, 
61.72% of the cost was related to medical ex-
penses and 64.08% of medical expenses were re-
lated to outpatient drugs. 75.17% of indirect costs 
and 23.52% of the total cost were due to prema-
ture death. 97.15% of total costs were related to 
outpatient care. The annual treatment cost per 
patient was USD 1,023. 
49.3% of direct medical costs paid in the form of 
out of pocket payments that it’s close to the total 
OOP in Iran. It should be noted that the out of 
pocket payment in 2002, 2005 and 2008, was 52.4, 
52 and 52.7 percent of total health care expendi-
ture, respectively (22). We shall pay for the results 
of other studies in this field and mention weak-
ness and strength of the study. 
In South Korea the economic costs of liver dis-
ease were KRW 5,858 billion in 2004, KRW 5,572 
billion in 2005, KRW 8,104 billion in 2006, KRW 
6,095 billion in 2007, and KRW 5,689 billion in 
2008 (9). The future production lost resulting 
from premature death was the greatest, from 
73.9% to 86.1%, followed by the direct medical 
costs, from 9.0% to 18.1%. The productivity loss 
resulting from absent from work accounts for 3.3-
5.5%, followed by the direct nonmedical costs 
such as transportation and caregiver costs, at 1.5-
2.5%. In liver diseases, liver carcinoma had the 
greatest portion of indirect cost. As it appears in 
direct costs in lee’s study is higher than our study 
(31% vs.73.9%) because in that study all of liver 
disease had been considered and as we know liver 
carcinoma has a higher mortality in liver diseases. 
Besides, in our study direct nonmedical cost con-
sist a little portion of costs that it correspond with 
that study (9). 
The socioeconomic cost of the HBV infection in 
1997 was 1078.3 billion won (USD 959.7 million), 
which 142.3 billion won or 13.2% being attributa-
ble to the costs of prevention and 225.4 billion 
won or 20.9% was attributable to HBV-related 
disease (23). The total societal costs (direct plus 
indirect) associated with HBV-related disease was 
936.1 billion won ($US 833.1 million) of which 
the 45.3% (377.4 million) was attributable to cir-
rhosis costs. In terms of disease-related direct 
costs alone (710.5 billion Won or $US 696.2 mil-
lion), the annual cost per patient was estimated 
1.37 million KRW ($US 1,219 dollars). In our 
study, the total direct and indirect costs were equal 
to USD 112.9 and USD 51.42 million dollars and 
total cost was estimated USD 164.32 million. 
Medical and non-medical direct costs were 101.42, 
and USD 11.48 million, respectively. In our study 
indirect cost is higher than that study (20.9% vs. 
31% of total costs), which probability is due to 
this point that they considered  all diseases related 
to hepatitis which the majority of them have lower 
disability and deaths in compare of liver cirrhosis 
(23). Also, both studies showed that the direct 
costs consist of a large part of the burden of dis-
ease. In South Korea, liver cirrhosis had 45.3 of 
total cost of HBV-related disease and other dis-
eases were responsible for 54.7% of costs. It has 
showed that cirrhosis impose a high portion of 
costs of HBV infection otherwise that it has a low 
prevalence (23). 
Lisa Inez study (24) examined premature death 
and the life years lost due to cirrhosis. Cirrhosis 
mortality consisted 48.7% and 24.1% of death 
caused by gastroenterology disease in men and 
women, respectively. On average about 15.5 po-
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tential productive years was lost in a death, for 
both sexes. Another study that examined the bur-
den of cirrhosis in Canada (25) showed that the 
cost of treatment of liver cirrhosis in the first year 
of illness for each patient is 983 dollars that is very 
close to 1023 dollars that we found. The differ-
ences between these two may be the result of dif-
ferent price of medical cares and inflation in drug 
cost because that study conducted in 2005.  
As it appears from the studies, direct costs usually 
consist of the higher portion of costs and indirect 
costs increase with increase life expectancy lost 
and deaths due to the disease. According to the 
fact and high mortality in liver cirrhosis, policy 
makers should be careful about and take policies 
for prevention and decrease of incidence and 
mortality of the disease. 
Like similar studies we have some limitations and 
assumptions that these may cause the actual costs 
of the illness in society be a little different from 
what we estimated. We shall pay to these limita-
tions, assumptions and weakness and strength of 
the study. 
This study was the first attempt to examining the 
economic burden of liver cirrhosis in Iran. Ac-
cording to lack of some data, such as prevalence 
of the disease, we used an estimation of them. Al-
so the annual probability of annual hospitalization 
didn’t exist, thus we survey medical records of the 
patient and interview with a sample of patient 
about their hospitalization, as well. We assume 
that all patients take the medical care that they 
need, but there may be some patients not receive 
the necessary care. Therefore, we may overesti-
mate the cost of the disease. On the other hand, 
this study had some strength points such as esti-
mating different component of costs like trans-
portation cost and production lost, the cost of 
disability for patients, families and in terms of in-
patient and outpatient care, separately, that usually 
in other studies didn’t pay to. Estimating the cost 
of outpatient treatment in terms of its compo-
nents, costs of outpatient visits, diagnostic tests 
and drugs, can be mentioned as other strength of 
the study. Also, we estimated out of pocket pay-
ments in inpatient and outpatient care, separately. 
It is recommended that future studies examine the 
costs of disease based on incidence approach and 
stages of liver cirrhosis. 
 
Conclusions 
 
Totally, the result of our study shows that liver 
cirrhosis imposes enormous economic burden on 
Iranian society. Therefore, policymakers should 
provide facilities and services for the prevention 
and treatment of the disease and according to high 
out of pocket in treatment process it seems we 
should promote the insurance programs for de-
creasing it, and complete the treatment of the dis-
ease especially in outpatient care that has a greater 
cost.  
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